C-MER Medical Holdings (SEHK:3309) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

3309 Aperçu des actions

C-MER Medical Holdings Limited, une société holding d'investissement, fournit des services ophtalmologiques sous la marque C-MER Dennis Lam à Hong Kong et en Chine continentale.

A propos de l'entreprise

3309 analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	2/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Se négocie à 77.5% en dessous de notre estimation de sa juste valeur

Devenu rentable cette année

Analyse des risques

Les revenus ont diminué de 23.6% par an au cours des 5 dernières années

C-MER Medical Holdings Limited Concurrents

China Resources Medical Holdings

SEHK:1515

HK$4.1b

Chaoju Eye Care Holdings

SEHK:2219

HK$1.9b

Rici Healthcare Holdings

SEHK:1526

HK$2.0b

Honliv Healthcare Management Group

SEHK:9906

HK$1.3b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour C-MER Medical Holdings
Historique des cours de bourse
Prix actuel de l'action	HK$2.24
Plus haut sur 52 semaines	HK$3.98
Plus bas sur 52 semaines	HK$2.19
Bêta	0.58
1Variation sur 1 mois	-12.16%
Variation sur 3 mois	-24.83%
Variation sur 1 an	-38.96%
3Variation sur 3 ans	-70.13%
Variation sur 5 ans	-53.91%
Évolution depuis l'introduction en bourse	-56.16%

Nouvelles et mises à jour récentes

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

Recent updates

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Feb 02

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Jan 17

Rendement pour les actionnaires

	3309	HK Healthcare	HK Marché
7D	-4.7%	-4.3%	0.3%
1Y	-39.0%	-29.9%	4.0%

Rendement vs Industrie: 3309 a sous-performé le secteur Hong Kong Healthcare qui a rapporté -30.6 % au cours de l'année écoulée.

Rendement vs marché: 3309 a sous-performé le marché Hong Kong qui a rapporté 6.2 % au cours de l'année écoulée.

Volatilité des prix

Is 3309's price volatile compared to industry and market?
3309 volatility
3309 Average Weekly Movement	4.4%
Healthcare Industry Average Movement	5.6%
Market Average Movement	6.3%
10% most volatile stocks in HK Market	13.1%
10% least volatile stocks in HK Market	3.3%

Cours de l'action stable: Le cours de l'action de 3309 a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 3309 ( 5% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2012	3,273	Dennis Lam	www.cmermedical.com

C-MER Medical Holdings Limited, une société holding d'investissement, fournit des services ophtalmologiques sous la marque C-MER Dennis Lam à Hong Kong et en Chine continentale. La société opère à travers quatre segments : HK Medical Business, Sales of Medical Consumables, Mainland China Ophthalmic Business et Mainland China Dental Business. Elle fournit des services dentaires, d'oncologie, d'esthétique médicale et de laboratoire, et vend des produits d'aide à la vision, tels que des lunettes et des lentilles, ainsi que des consommables médicaux.

C-MER Medical Holdings Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de C-MER Medical Holdings se comparent-ils à sa capitalisation boursière ?
3309 statistiques fondamentales
Capitalisation boursière	HK$2.79b
Bénéfices(TTM)	HK$62.00m
Recettes(TTM)	HK$1.92b

44.9x

Ratio P/E

1.4x

Ratio P/S

Le site 3309 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
3309 compte de résultat (TTM)
Recettes	HK$1.92b
Coût des recettes	HK$1.31b
Marge brute	HK$618.96m
Autres dépenses	HK$556.96m
Les revenus	HK$62.00m

Derniers bénéfices déclarés

Dec 31, 2023

Prochaine date de publication des résultats

Aug 29, 2024

Résultat par action (EPS)	0.05
Marge brute	32.17%
Marge bénéficiaire nette	3.22%
Ratio dettes/capitaux propres	1.2%

Quelles ont été les performances à long terme de 3309?

Voir les performances historiques et les comparaisons

3309 Aperçu des actions

Récompenses

Analyse des risques

C-MER Medical Holdings Limited Concurrents

SEHK:1515

HK$4.1b

SEHK:2219

HK$1.9b

SEHK:1526

HK$2.0b

SEHK:9906

HK$1.3b

Historique des prix et performances

Nouvelles et mises à jour récentes

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

Recent updates

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 12% to HK$4.50

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

A Look At The Intrinsic Value Of C-MER Eye Care Holdings Limited (HKG:3309)

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Capital Allocation Trends At C-MER Eye Care Holdings (HKG:3309) Aren't Ideal

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

Is C-MER Eye Care Holdings (HKG:3309) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

Executive Director exercised options to buy HK$1.7m worth of stock.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Update: C-MER Eye Care Holdings (HKG:3309) Stock Gained 25% In The Last Year

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Rendement pour les actionnaires

Volatilité des prix